Literature DB >> 31770161

How much astigmatism to treat in cataract surgery.

Rohini R Sigireddi1, Mitchell P Weikert.   

Abstract

PURPOSE OF REVIEW: Astigmatism correction in cataract surgery is a common surgical challenge. Although there are numerous approaches to its treatment during cataract surgery, there remains a lack of consensus on what level of postoperative astigmatism to target. We examine the literature to determine the effect of astigmatism on visual function and provide a recommendation on how much to treat in cataract surgery. RECENT
FINDINGS: Distance visual acuity decreases as myopic, hyperopic, or mixed astigmatism increases. Near visual acuity decreases with hyperopic astigmatism but improves with myopic astigmatism. The effect of astigmatism is generally independent of axis; however, against-the-rule (ATR) astigmatism with mild myopia may benefit reading. A progressive ATR shift occurs with age whether or not an individual undergoes cataract surgery. In the presence of higher order aberrations, correction of astigmatism below 0.5 D shows minimal practical benefit. Presbyopia-correcting intraocular lenses (IOLs) are sensitive to astigmatism but achieve distance visual acuities similar to monofocal IOLs and reach their full near and/or intermediate potential when residual astigmatism 0.5 D or less.
SUMMARY: In cataract surgery, we recommend correction to 0.5 D or less of postoperative residual astigmatism to achieve optimum visual function and patient satisfaction following cataract surgery.

Entities:  

Mesh:

Year:  2020        PMID: 31770161     DOI: 10.1097/ICU.0000000000000627

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  1 in total

1.  Astigmatism profile in the elderly population: Tehran Geriatric Eye Study.

Authors:  Hassan Hashemi; Amir Asharlous; Abbasali Yekta; Mohammadereza Aghamirsalim; Payam Nabovati; Mohammad Mehdi Sadoughi; Mehdi Khabazkhoob
Journal:  Jpn J Ophthalmol       Date:  2022-08-10       Impact factor: 2.211

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.